NASDAQ:LUMO
Lumos Pharma Inc. Stock Company Profile
$2.77
+0.0100 (+0.362%)
At Close: Apr 26, 2024
Information
4200 Marathon Boulevard, Suite 200
Austin TX 78756
512 215 2630
www.lumos-pharma.com
Industry: Biotechnology
Sector: Healthcare
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
